Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.

Publication ,  Journal Article
Bhavsar, NA; Harrison, MR; Hirsch, BR; Creel, P; Wolf, SP; Samsa, GP; Abernethy, AP; Simantov, R; Borham, A; George, DJ
Published in: Cancer Invest
May 28, 2017

The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routine clinical practice across the United States. This observational study is designed to enroll 500 patients with previously untreated mRCC from approximately 60 academic and community treatment sites; as of December 7, 2016, 500 patients have enrolled at 54 sites. Key endpoints include real-world data on reasons for treatment initiation and discontinuation; treatment regimens; disease progression; patient-reported outcomes; and healthcare resource utilization in this patient population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

May 28, 2017

Volume

35

Issue

5

Start / End Page

333 / 344

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Research Design
  • Registries
  • Quality of Life
  • Prospective Studies
  • Practice Patterns, Physicians'
  • Patient Reported Outcome Measures
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bhavsar, N. A., Harrison, M. R., Hirsch, B. R., Creel, P., Wolf, S. P., Samsa, G. P., … George, D. J. (2017). Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Invest, 35(5), 333–344. https://doi.org/10.1080/07357907.2017.1289215
Bhavsar, Nrupen A., Michael R. Harrison, Bradford R. Hirsch, Patricia Creel, Steve P. Wolf, Greg P. Samsa, Amy P. Abernethy, Ronit Simantov, Azah Borham, and Daniel J. George. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.Cancer Invest 35, no. 5 (May 28, 2017): 333–44. https://doi.org/10.1080/07357907.2017.1289215.
Bhavsar, Nrupen A., et al. “Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.Cancer Invest, vol. 35, no. 5, May 2017, pp. 333–44. Pubmed, doi:10.1080/07357907.2017.1289215.
Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, Abernethy AP, Simantov R, Borham A, George DJ. Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer. Cancer Invest. 2017 May 28;35(5):333–344.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

May 28, 2017

Volume

35

Issue

5

Start / End Page

333 / 344

Location

England

Related Subject Headings

  • United States
  • Treatment Outcome
  • Time Factors
  • Research Design
  • Registries
  • Quality of Life
  • Prospective Studies
  • Practice Patterns, Physicians'
  • Patient Reported Outcome Measures
  • Oncology & Carcinogenesis